M&A Deal Summary |
|
|---|---|
| Date | 2006-12-22 |
| Target | Euroscreen Products SA |
| Sector | Medical Products |
| Buyer(s) | Revvity |
| Sellers(s) | Ogeda SA |
| Deal Type | Divestiture |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1937 |
| Sector | Medical Products |
| Employees | 11,000 |
| Revenue | 2.8B USD (2024) |
Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Revvity was formed in 1937 and is based in Waltham, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 6 of 37 |
| Sector: Medical Products M&A | 1 of 11 |
| Type: Divestiture M&A Deals | 1 of 2 |
| Country: Belgium M&A | 1 of 1 |
| Year: 2006 M&A | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2006-05-01 |
Spectral Genomics
Houston, Texas, United States Spectral Genomics, Inc. is a global supplier of innovative products for human genetics and performs Genomic Profiling(SM) services for customers in academic and industrial research laboratories. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2007-11-15 |
ViaCord
Cambridge, Massachusetts, United States ViaCord has been providing the highest quality, umbilical cord blood stem cell collections for families, and has been involved in cutting edge research to find new stem cell therapies for diseases like cancer, juvenile diabetes, and heart disease. s. the is part of PerkinElmer, a global company committed to improving human and environmental health. PerkinElmer’s financial strength and stability provides reassurance to families for the safekeeping of their stem cell collections, now and in the future. |
Buy | $300M |
Ogeda SA is a clinical-stage drug discovery company that invents and develops small molecule drug candidates targeting GPCRs. Ogeda's orally-available and proprietary lead drug candidate fezolinetant (ESN364) is currently in Phase2 clinical development for the treatment of women's health disorders. Ogeda has additional small molecules targeting GPCRs in pre-clinical development in multiple therapeutic areas including inflammatory and autoimmune diseases.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Medical Products M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| Country: Belgium M&A | 1 of 1 |
| Year: 2006 M&A | 1 of 1 |
